(Press-News.org) Feeding an intestinal enzyme to mice kept on a high-fat diet appears to prevent the development of metabolic syndrome – a group of symptoms associated with type 2 diabetes, cardiovascular disease and fatty liver – and to reduce symptoms in mice that already had the condition. In their report published online in PNAS Early Edition, Massachusetts General Hospital (MGH) investigators describe how dietary supplementation with intestinal alkaline phosphatase (IAP) reduced the inflammation believed to underlie metabolic syndrome by blocking a toxic molecule found on the surface of many bacteria.
"For the first time we are targeting production of inflammatory factors in the intestinal tract to prevent the systemic problem of the metabolic syndrome," says Richard Hodin, MD, of the MGH Department of Surgery, the study's senior author. "Animal studies have shown the gut to be the likely source of these factors, and we have previously shown in laboratory studies that IAP can block their activity. There are human studies that correlate low-grade systemic inflammation with the metabolic syndrome, so we expect that IAP's ability to interfere with the process will apply to humans as well."
Encompassing symptoms including obesity, glucose intolerance, insulin resistance, hypertension and lipid abnormalities, metabolic syndrome affects more than one-third of the U.S. population and significantly increases the risk for cardiovascular disease and type 2 diabetes. A possible contributor to metabolic syndrome is increased blood levels of lipopolysaccharide (LPS), a molecule found on the surface of many gut bacteria and responsible for their toxic effects when it passes through the intestinal wall into the systemic circulation. A persistent increase in circulating LPS, a condition called endotoxemia, causes low-grade inflammation – a primary aspect of metabolic syndrome – throughout the body. LPS is known to bind to fat, and several studies have shown that a high-fat diet raises systemic LPS levels in animals and humans, increasing both intestinal inflammation and the permeability of the intestinal wall, allowing additional LPS to pass into the bloodstream.
Previous work in Hodin's lab showed that IAP, which is produced by cells lining the small intestine, can block the action of LPS, leading to the hypothesis that the enzyme could help prevent the systemic inflammation associated with a high-fat diet. In a series of experiments described in the current study, the investigators showed the following:
mice in which IAP expression was either knocked out or suppressed developed endotoxemia, overexpression of inflammatory factors and symptoms of metabolic syndrome;
feeding IAP to mice on a high-fat diet prevented weight gain and fat accumulation and reduced development of metabolic syndrome;
feeding IAP to mice that had developed metabolic syndrome as a result of a high-fat diet, reduced endotoxemia, inflammatory factors and symptoms such as glucose intolerance;
feeding IAP to mice on a low-fat diet slightly improved glucose metabolism but significantly improved lipid metabolism.
The researchers note that IAP is naturally found in an environment containing many bacterial factors that induce inflammation – suggesting that it may suppress the activity of additional factors – and that several related enzymes should be investigated for shared protective abilities.
"While our findings clearly predict that IAP supplementation could have the same effect in human patients, future studies are required to test this directly," explains Hodin, a professor of Surgery at Harvard Medical School (HMS). "We need a formulation of the enzyme that can be safely given to humans – something we are working to develop – which we then can test as a prevention or treatment for metabolic syndrome, a contributor to the number one cause of patient death in this country."
###
Mahdu Malo, PhD, MBBS, of the MGH Department of Surgery, an assistant professor of Surgery at HMS, is corresponding author of the PNAS Early Edition report and was instrumental in the development of the study concept along with Hodin. Kanakaraju Kaliannan, MD; Sulaiman R. Hamarneh, MBBS; and Konstantinos P. Economopoulos, MD – all of MGH Surgery – are co-lead authors. This work was supported by National Institutes of Health grants R01DK050623, R01DK047186 and 2P30 DK43351, the MGH Department of Surgery, and the Bill and Melinda Gates Foundation.
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine. In July 2012, MGH moved into the number one spot on the 2012-13 U.S. News & World Report list of "America's Best Hospitals."
Adding intestinal enzyme to diets of mice appears to prevent, treat metabolic syndrome
2013-04-09
ELSE PRESS RELEASES FROM THIS DATE:
Nearly half of breast cancer patients at risk of having BRCA mutations not sent for genetic testing
2013-04-09
WASHINGTON, DC -- Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation – based on age, diagnosis, and family history of breast or ovarian cancer – reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.
The findings, which will be presented during the American Association for Cancer Research Annual Meeting 2013 (Presentation #1358), were drawn from surveys completed by 2,258 women between 18 ...
Adding cetuximab to chemotherapy enables select patients with advanced colorectal cancer and liver metastasis to undergo surgery, extending survival by several months
2013-04-09
In this News Digest:
Summary of a study being published online April 8, 2013 in the Journal of Clinical Oncology, reports that adding cetuximab (Erbitux) to chemotherapy enabled previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis.
The combination of cetuximab and chemotherapy extended median overall survival for this population of patients by 10 months compared with chemotherapy alone.
Quote for attribution to Neal Meropol, MD, American Society of Clinical Oncology Cancer Communications Committee member ...
Month of birth impacts on immune system development
2013-04-09
Newborn babies' immune system development and levels of vitamin D have been found to vary according to their month of birth, according to new research.
The research, from scientists at Queen Mary, University of London and the University of Oxford, provides a potential biological basis as to why an individual's risk of developing the neurological condition multiple sclerosis (MS) is influenced by their month of birth. It also supports the need for further research into the potential benefits of vitamin D supplementation during pregnancy.
Around 100,000 people in the ...
Study finds key to calling back-up help when tumor-fighter p53 goes down
2013-04-09
WASHINGTON, D.C. – Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.
In a presentation at the AACR Annual Meeting 2013, scientists from The University of Texas MD Anderson Cancer Center demonstrate that tumor suppression can be restored in mice that lack p53 by knocking out the ∆N isoforms of p63 and p73 that interfere with tumor ...
AACR news: XL-184 (Cabozantinib) goes 12-for-12 in colorectal cancer explants
2013-04-09
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013.
"With molecularly targeted agents, we typically see 3 or 4 CRC explant models with a significant decrease in tumor growth. Here we have a drug that was active in every explant we tested. It's really exciting," says John Arcaroli, PhD, investigator at the University ...
AACR news: Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine
2013-04-09
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and so more susceptible to the drugs. That's what the traditional anti-malaria drug, chloroquine, does – it inhibits autophagy. Existing clinical trials are testing chloroquine/chemotherapy combinations against breast cancer.
Research presented at the AACR Annual Meeting 2013 shows that some breast cancer subtypes depend on autophagy more than others – and ...
Possible predictive biomarker for patients who may respond to autophagy inhibitors
2013-04-09
WASHINGTON, DC – Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy.
A team led by researchers from the ...
Surface diffusion plays a key role in defining the shapes of catalytic nanoparticles
2013-04-09
Controlling the shapes of nanometer-sized catalytic and electrocatalytic particles made from noble metals such as platinum and palladium may be more complicated than previously thought.
Using systematic experiments, researchers have investigated how surface diffusion – a process in which atoms move from one site to another on nanoscale surfaces – affects the final shape of the particles. The issue is important for a wide range of applications that use specific shapes to optimize the activity and selectivity of nanoparticles, including catalytic converters, fuel cell ...
Thinking you're old and frail
2013-04-09
Older adults who categorise themselves as old and frail encourage attitudinal and behavioural confirmation of that identity.
This is the conclusion of a study conducted by Krystal Warmoth and colleagues at University of Exeter Medical School, which is being presented today, 9th April 2013, at the British Psychological Society Annual Conference in Harrogate, UK.
Krystal Warmoth interviewed 29 older adults in the South West of England face-to-face. Interviews conducted asked about their experiences of ageing and frailty. Self-perception and identification related to ...
Particles changing angle: Unexpected orientation in capillaries
2013-04-09
When small particles flow through thin capillaries, they display an unusual orientation behaviour. This has recently been discovered by a research team led by Prof. Stephan Förster and Prof. Walter Zimmermann (University of Bayreuth, Germany) at the X-ray sources DORIS III and PETRA III of the research centre DESY in Hamburg, Germany. The discovery is of major importance for spinning processes designed for the production of synthetic fibres, and for the understanding of vascular stenosis. The scientists of Bayreuth University, the Radboud University Nijmegen (Netherlands), ...